Photo by cdc from unsplash
Treatment with antibodies directed against programed‐cell death ligand 1 (PD‐L1) is a novel therapy for patients with gestational trophoblastic disease. Assessment of PD‐L1 expression in tumor tissue is commonly used… Click to show full abstract
Treatment with antibodies directed against programed‐cell death ligand 1 (PD‐L1) is a novel therapy for patients with gestational trophoblastic disease. Assessment of PD‐L1 expression in tumor tissue is commonly used to identify patients who might benefit from anti‐PD‐L1 treatment. Multiple antibodies are available to detect PD‐L1‐expressing cells, and percentages of PD‐L1‐expressing cells in samples of patients with gestational trophoblastic disease indicated by these antibodies differ substantially. This raises the question which PD‐L1 antibody best reflects PD‐L1 expression to select patients for treatment.
Journal Title: Acta Obstetricia et Gynecologica Scandinavica
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!